Monopar Therapeutics Inc
MNPR
Company Profile
Business description
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicinfor the treatmentof soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.
Contact
1000 Skokie Boulevard
Suite 350
WilmetteIL60091
USAT: +1 847 388-0349
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
16
Stocks News & Analysis
stocks
Are small caps finally back?
Does renewed investor interest point to a structural shift in the underperforming factor?
stocks
Chart of the Week: Modest earnings growth at odds with overvalued bank shares
The latest update from our Industry Pulse report.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,329.10 | 50.90 | 0.55% |
| CAC 40 | 8,225.78 | 18.91 | 0.23% |
| DAX 40 | 24,207.79 | 56.66 | 0.23% |
| Dow JONES (US) | 46,759.58 | 169.17 | 0.36% |
| FTSE 100 | 9,578.57 | 63.57 | 0.67% |
| HKSE | 25,967.98 | 186.21 | 0.72% |
| NASDAQ | 22,965.46 | 225.07 | 0.99% |
| Nikkei 225 | 48,641.61 | 666.18 | -1.35% |
| NZX 50 Index | 13,377.10 | 70.66 | 0.53% |
| S&P 500 | 6,744.12 | 44.72 | 0.67% |
| S&P/ASX 200 | 9,032.80 | 46.60 | 0.52% |
| SSE Composite Index | 3,922.41 | 8.65 | 0.22% |